Korro Bio (KRRO) Cost of Revenue (2019)

Korro Bio (KRRO) posted Cost of Revenue of $16.0 million for Q3 2019.

Korro Bio (KRRO) Cost of Revenue (2019) Analysis & Trends

Korro Bio's Cost of Revenue history runs 1 years deep, the most recent figure standing at $16.0 million for Q3 2019.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cost of Rev (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 167.22 Mn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 392.80 Mn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 296.00 Mn
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 145.00 Mn
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Korro Bio 123.70 Mn 9.73 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2019 16.00 Mn
Sep 30, 2019 16.00 Mn